Humacyte, Inc.
Humacyte, Inc. (HUMA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · HUMA · as of Jun 8, 2026
Key Statistics
Explore Humacyte, Inc. Data
huma stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 90.9%
The HUMA analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $5.58, representing +298.57% upside from the current price of $1.40.
Competitors & Peers
huma competitorsHUMA
ACHV
ARCT
AVIR
FHTX
IMRXStock Performance
Full HistoryAbout Humacyte, Inc.
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locatio…
what is humacyte, inc. · huma stock overview · humacyte, inc. company profile · who is humacyte, inc. ceo · huma NASDAQ · humacyte, inc. headquarters · humacyte, inc. business segments
About Stock Overview & Key Data
Humacyte, Inc. (HUMA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 1, 2020. As of the latest trading session, HUMA stock price is $1.40, with a market capitalization of $235.2M. The stock has returned -45.31% over the past 12 months and +45.76% year-to-date.
According to 11 Wall Street analysts, the consensus rating for Humacyte, Inc. stock is Buy, with an average 12-month price target of $5.58. In fiscal year 2025, Humacyte, Inc. reported revenue of $2.0M and net income of -$40.8M. For detailed data — including Humacyte, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Humacyte, Inc. (HUMA) stock price is $1.40. The stock is traded on NASDAQ under the ticker symbol HUMA. The 52-week range is $0.55 – $2.93.